CDC Group Commits US $100 Million To African Development Partners III

CDC Group plc (“CDC”), the UK’s development finance institution and impact investor, has announced a US $100 million commitment to African Development Partners III, the Fund advised by Development Partners International LLP (DPI) – a leading pan-African private equity firm.

CDC’s latest commitment supports ADP III fundraise as it closes at the US $900 million, becoming one of the largest funds dedicated to investing in Africa.

ADP III will target medium-sized and large companies in Africa, thereby facilitating greater job creation, economic diversification, and market expansion, whilst also funding essential services through corporate taxes.

As part of its strategy, the fund will also focus on innovation-led businesses that are transforming critical sectors such as healthcare and agriculture, and are in turn, helping to foster economic growth across the continent.

CDC’s commitment reaffirms the DFI’s confidence in DPI’s hands-on approach to value creation as the fund manager continues to make strong strides in ESG and development impact, whilst also embedding gender lens investing and climate change into its investment mandate.

ADP III has been recognized as the first 2X Flagship Fund, as part of the global 2X Challenge, which speaks to DPI’s commitment to gender-lens investing and creating economic opportunities for women in Africa.

Supported by CDC, DPI has trained its investment teams on opportunity-led gender finance and has embedded appropriate safeguarding measures within the fund and across its portfolio. DPI has also been developing tools to assess climate-related risks and opportunities in their investments.

The UK’s development finance institution has been an important partner for DPI since the manager’s inaugural fund in 2008 and anchored the subsequent ADP II fund, committing the US $75m at the first close in 2013. CDC’s investment in ADP III strengthens the partnership with DPI, enabling the availability of greater capital to CDC’s target markets.